Partner with us

The Institute for Molecular Bioscience is Australia's #1 research institute. We were established to position Queensland as a global epicentre of drug discovery, and to create a full pipeline of capabilities from basic discovery science to translational research, spanning genomics, biology and chemistry.

Our vision is a world with a cure for every disease, and our partners are an integral part of this vision.

We have a track record of partnering to deliver translational outcomes. We have created multibillion-dollar spin-out companies developing treatments for stroke, Parkinson's disease and cancer, and helped deliver the world's first environmentally friendly pesticides to market.

IMB has the expertise and facilities to address globally relevant and organisation-specific research problems. We seek creative approaches to solve problems, and welcome the talent and ideas of our partners.

Our capabilites

We have a broad range of capabilities that span a number of research areas. In particular, we have expertise in:

  • Pharmacogenomics
  • Statistical genetics
  • AI diagnostics
  • Drug discovery

We are developing treatments and diagnostics, and discovering more about the fundamental biology, of the following diseases:

  • AMR, with a focus on antibiotic discovery
  • Cardiovascular disease
  • Stroke
  • Pain
  • Endometriosis
  • Cancer
  • Non-alcoholic steatohepatitis (NASH)
  • Amyotrophic lateral sclerosis/Motor neurone disease (ALS/MND)

To learn more about our capabilities and expertise in these areas, please contact our Research Partnership team.


Norbert Kienzle

Download our fast facts              

Institute Molecular Bioscience_Infographic            

A protein complex called an inflammasome.

Case study: Inflazome

One of the largest biotech deals in Australian history was the sale of a start-up company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland, including IMB researchers, and Trinity College Dublin.

The company, Inflazome, was acquired by Swiss multinational pharma company Roche for an upfront payment of ~$A600 million, plus additional payments based on the achievement of certain milestones.

Inflazome was founded in 2016 to develop drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes, protein complexes that are understood to drive many chronic inflammatory conditions. The acquisition gives Roche full rights to Inflazome’s portfolio of drugs, which includes candidates in clinical trials.